<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-22T14:42:36Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/10192" metadataPrefix="edm">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/10192</identifier><datestamp>2026-01-19T09:16:16Z</datestamp><setSpec>com_10259_3844</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_3845</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xsi:schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">
<edm:ProvidedCHO rdf:about="http://hdl.handle.net/10259/10192">
<dc:creator>Sanz Villafruela, Juan</dc:creator>
<dc:creator>Bermejo Casadesus, Cristina</dc:creator>
<dc:creator>Zafon, Elisenda</dc:creator>
<dc:creator>Martínez Alonso, Marta</dc:creator>
<dc:creator>Durá, Gema</dc:creator>
<dc:creator>Heras Vidaurre, Aránzazu</dc:creator>
<dc:creator>Soriano Díaz, Iván</dc:creator>
<dc:creator>Giussani, Angelo</dc:creator>
<dc:creator>Ortí, Enrique .</dc:creator>
<dc:creator>Tebar, Francesc</dc:creator>
<dc:creator>Espino Ordóñez, Gustavo</dc:creator>
<dc:creator>Massaguer Vall-Llovera, Anna</dc:creator>
<dc:date>2024-10</dc:date>
<dc:description>Ir(III) and Ru(II) polypyridyl complexes are promising photosensitizers (PSs) for photodynamic therapy (PDT)&#xd;
due to their outstanding photophysical properties. Herein, one series of cyclometallated Ir(III) complexes and&#xd;
two series of Ru(II) polypyridyl derivatives bearing three different thiazolyl-β-carboline N^N′ ligands have been&#xd;
synthesized, aiming to evaluate the impact of the different metal fragments ([Ir(C^N)2]&#xd;
+ or [Ru(N^N)2]&#xd;
2+) and&#xd;
N^N’ ligands on the photophysical and biological properties. All the compounds exhibit remarkable photo&#xd;
stability under blue-light irradiation and are emissive (605 &lt; λem &lt; 720 nm), with the Ru(II) derivatives dis&#xd;
playing higher photoluminescence quantum yields and longer excited state lifetimes. The Ir PSs display pKa&#xd;
values between 5.9 and 7.9, whereas their Ru counterparts are less acidic (pKa > 9.3). The presence of the&#xd;
deprotonated form in the Ir-PSs favours the generation of reactive oxygen species (ROS) since, according to&#xd;
theoretical calculations, it features a low-lying ligand-centered triplet excited state (T1 = 3&#xd;
LC) with a long&#xd;
lifetime. All compounds have demonstrated anticancer activity. Ir(III) complexes 1–3 exhibit the highest cyto&#xd;
toxicity in dark conditions, comparable to cisplatin. Their activity is notably enhanced by blue-light irradiation,&#xd;
resulting in nanomolar IC50 values and phototoxicity indexes (PIs) between 70 and 201 in different cancer cell&#xd;
lines. The Ir(III) PSs are also activated by green (with PI between 16 and 19.2) and red light in the case of&#xd;
complex 3 (PI = 8.5). Their antitumor efficacy is confirmed by clonogenic assays and using spheroid models. The&#xd;
Ir(III) complexes rapidly enter cells, accumulating in mitochondria and lysosomes. Upon photoactivation, they&#xd;
generate ROS, leading to mitochondrial dysfunction and lysosomal damage and ultimately cell apoptosis.&#xd;
Additionally, they inhibit cancer cell migration, a crucial step in metastasis. In contrast, Ru(II) complex 6 exhibits moderate mitochondrial activity. Overall, Ir(III) complexes 1–3 show potential for selective light-controlled cancer treatment, providing an alternative mechanism to chemotherapy and the ability to inhibit lethal cancer cell dissemination.</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>http://hdl.handle.net/10259/10192</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>Elsevier</dc:publisher>
<dc:title>Insights into the anticancer photodynamic activity of Ir(III) and Ru(II) polypyridyl complexes bearing β-carboline ligands</dc:title>
<dc:type>info:eu-repo/semantics/article</dc:type>
<edm:type>TEXT</edm:type>
</edm:ProvidedCHO>
<ore:Aggregation rdf:about="http://hdl.handle.net/10259/10192#aggregation">
<edm:aggregatedCHO rdf:resource="http://hdl.handle.net/10259/10192"/>
<edm:dataProvider>RIUBU. Repositorio Institucional de la Universidad de Burgos</edm:dataProvider>
<edm:isShownAt rdf:resource="http://hdl.handle.net/10259/10192"/>
<edm:isShownBy rdf:resource="https://riubu.ubu.es/bitstream/10259/10192/1/Sanz-ejomc_2024.pdf"/>
<edm:object rdf:resource="https://riubu.ubu.es/bitstream/10259/10192/4/Sanz-ejomc_2024.pdf.jpg"/>
<edm:provider>Hispana</edm:provider>
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</ore:Aggregation>
<edm:WebResource rdf:about="https://riubu.ubu.es/bitstream/10259/10192/1/Sanz-ejomc_2024.pdf">
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</edm:WebResource>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>